HeartFlow, a Mountain View, CA-based precision heart care company, raised $215M in Series F funding.
The round was led by Bain Capital Life Sciences with participation from new investor, Janus Henderson Investors, and existing investors, including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP and Wellington Management.
The company intends to use the funds to extend the demand for its commercial products, support clinical evidence and advance its comprehensive product portfolio.
Led by CEO John Farquhar, HeartFlow is a medical technology company offering HeartFlow Analysis, a non-invasive personalized cardiac test, which allows physicians to make care decisions for their patients with suspected coronary artery disease. With the recent FDA clearance of new products, the company now provides non-invasive coronary artery anatomy (RoadMap™ analysis), physiology (HeartFlow® FFRCT), and plaque information (Plaque analysis) based on CCTA. These products enable physicians to gain more understanding of a patient’s CAD and are the most comprehensive approach to predict risk of a heart attack.